Brookline Capital Acquisition Estimates CRBU FY2030 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at Brookline Capital Acquisition issued their FY2030 earnings per share estimates for shares of Caribou Biosciences in a note issued to investors on Wednesday, February 4th. Brookline Capital Acquisition analyst L. Cann forecasts that the company will post earnings of ($5.28) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.20 million during the quarter, compared to the consensus estimate of $1.94 million. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.

CRBU has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Truist Financial set a $7.00 price objective on shares of Caribou Biosciences in a research report on Tuesday, November 4th. HC Wainwright upped their price objective on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Citigroup boosted their target price on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Caribou Biosciences Stock Performance

Caribou Biosciences stock opened at $1.57 on Friday. The stock’s 50 day moving average price is $1.65 and its 200 day moving average price is $1.94. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.54. The firm has a market capitalization of $146.75 million, a PE ratio of -0.92 and a beta of 2.61.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Caribou Biosciences by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,226,926 shares of the company’s stock valued at $9,849,000 after buying an additional 137,060 shares during the period. Millennium Management LLC raised its stake in shares of Caribou Biosciences by 107.4% in the 3rd quarter. Millennium Management LLC now owns 3,216,535 shares of the company’s stock valued at $7,495,000 after acquiring an additional 1,665,946 shares in the last quarter. Aberdeen Group plc raised its position in shares of Caribou Biosciences by 54.7% in the third quarter. Aberdeen Group plc now owns 1,388,905 shares of the company’s stock valued at $3,236,000 after purchasing an additional 491,326 shares during the period. Bank of America Corp DE raised its holdings in Caribou Biosciences by 32.8% in the 3rd quarter. Bank of America Corp DE now owns 1,074,442 shares of the company’s stock worth $2,503,000 after acquiring an additional 265,542 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after purchasing an additional 463,391 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.